Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 251

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance)

Open access
Smith, Matthew R., Halabi, Susan, Ryan, Charles J., Hussain, Arif, Vogelzang, Nicholas, Stadler, Walter, Hauke, Ralph J., Monk, J. Paul, Saylor, Philip, Bhoopalam, Nirmala, Saad, Fred, Sanford, Ben, Kelly, W. Kevin, Morris, Michael, Small, Eric J.·2014·Journal of Clinical Oncology

Abstract

Purpose: Zoledronic acid decreases the risk for skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases but its role earlier in the natural history of the disease is unknown. This phase III study evaluated the efficacy and safety of earlier treatment with zoledronic acid in men with castration-sensitive metastatic prostate cancer. Patients and Methods: Men with castration-sensitive prostate cancer and bone metastases whose androgen-deprivation therapy was initiated within 6 months of study entry were randomly assigned in a blinded 1:1 ratio to receive zoledronic acid (4 mg intravenously every 4 weeks) or a placebo. After their disease progressed to castration-resistant status, all patients received open-label treatment with zoledronic acid. The primary end point was time to first SRE, defined as radiation to bone, clinical fracture, spinal cord compression, surgery to bone, or death as a result of prostate cancer. Target accrual was 680 patients. Primary analysis was planned after 470 SREs. The study was discontinued prematurely (645 patients; 299 SREs) after the corporate supporter withdrew study drug supply. Results: Early zoledronic acid was not associated with increased time to first SRE. The median time to first SRE was 31.9 months in the zoledronic acid group (95% CI, 24.2 to 40.3) and 29.8 months in the placebo group (95% CI, 25.3 to 37.2; hazard ratio, 0.97; 95% CI, 0 to 1.17; one-sided stratified log-rank P = .39). Overall survival was similar between the groups (hazard ratio, 0.88; 95% CI, 0.70 to 1.12; P = .29). Rates of adverse events were similar between the groups. Conclusion: In men with castration-sensitive prostate cancer and bone metastases, early treatment with zoledronic acid was not associated with lower risk for SREs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2013.51.6500

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 7×

    “In a randomized controlled trial of 1,199 men with metastatic CRPC and disease progression after docetaxel chemotherapy, enzalutamide was associated with improved overall survival and superiority over placebo for all secondary end points including time to first SRE (HR, 0.69; 95% CI, 0.57 to 0.84; P .001).12 In anothe…”
    BackgroundInfluentialSelf-citation
  • Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer

    Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., Logue, J., Seke, M., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213755 · Cited by 3,408

    Self-citation

Show all 2 references

Cited by

See all 251

Metadata

Authors
Smith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., Hauke, R. J., Monk, J. P., Saylor, P., Bhoopalam, N., Saad, F., Sanford, B., Kelly, W. K., Morris, M., & Small, E. J.
Venue
Journal of Clinical Oncology
Published
2014-04-10
Volume
32
Issue
11
Pages
1143-1150
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2119319209
Cited by
251
References
2
FWCI
13.50
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). https://app.cochat.ai/papers/10.1200/jco.2013.51.6500
The paper
Smith, M. R., Halabi, S., Ryan, C. J., Hussain, A., Vogelzang, N., Stadler, W., Hauke, R. J., Monk, J. P., Saylor, P., Bhoopalam, N., Saad, F., Sanford, B., Kelly, W. K., Morris, M., & Small, E. J. (2014). Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). Journal of Clinical Oncology. https://doi.org/10.1200/jco.2013.51.6500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.